"Thinking isn't agreeing or disagreeing. That's voting."
Nick has worked in the pharmaceutical industry for nearly 25 years on the client side as well as in consulting and investment banking. He specialises in business development and advises pharma and biotech companies, investment banks and venture capitalists on issues including partnering, M&A and strategic exits.
Following an early scientific career, he joined Sterling Winthrop in regulatory affairs and then rapidily progressed to business development. Nick has been Global Head of Pharmaceutical Business Development at Hoffmann-La Roche, Head of Corporate M&A for Novartis and Managing Director for Bear Stearns leading their European Pharma M&A efforts. His experience includes consultancy, both independently and with AT Kearney.
Nick has an MBA from Cranfield University School of Management, UK, an MSc from London University and a BSc from Sheffield University, UK.